Summit Therapeutics (SMMT) Cash from Discontinued Operations (2016 - 2020)
Summit Therapeutics filings provide 7 years of Cash from Discontinued Operations readings, the most recent being 7447000.0 for Q1 2020.
- Quarterly Cash from Discontinued Operations fell 192.73% to 7447000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was 67905101.71 through Mar 2020, down 427.55% year-over-year, with the annual reading at 33910000.0 for FY2019, N/A changed from the prior year.
- Cash from Discontinued Operations hit 7447000.0 in Q1 2020 for Summit Therapeutics, up from 46907101.71 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 18881463.71 in Q3 2018 and bottomed at 46907101.71 in Q4 2019.
- Average Cash from Discontinued Operations over 5 years is 6255852.77, with a median of 7328500.0 recorded in 2019.
- Peak annual rise in Cash from Discontinued Operations hit 188.73% in 2018, while the deepest fall reached 297.35% in 2018.
- Summit Therapeutics' Cash from Discontinued Operations stood at 8812000.0 in 2016, then skyrocketed by 103.69% to 325393.37 in 2017, then tumbled by 3855.3% to 12219492.16 in 2018, then tumbled by 283.87% to 46907101.71 in 2019, then skyrocketed by 84.12% to 7447000.0 in 2020.
- Per Business Quant, the three most recent readings for SMMT's Cash from Discontinued Operations are 7447000.0 (Q1 2020), 46907101.71 (Q4 2019), and 7210000.0 (Q3 2019).